CSP Technologies, Inc. introduces Activ-Seal orifice-reducing closure with desiccant technology

  • Aptar CSP Technologies

CSP Technologies, Inc., a leader in packaging solutions that ensure product protection, enhance brand recognition and improve consumer experiences – has developed Activ-Seal™ closures, with gas scavenging technology built directly into an induction-sealed, tamper-evident screw cap.

The closure’s orifice-reducing element is affixed onto the top of the bottle during the induction sealing process.  It is covered by a lift and peel foil seal which, once removed, enables metered dosing. The scavenging component, offering combinations of moisture, volatile organic compounds (VOC), and odor management, is permanently positioned on the underside of the orifice reducer, ensuring the product protection never leaves the bottle, even after opening.

Offering optimized capacity and uptake rates, Activ-Seal closures offer significant improvement over more traditional methods of ensuring product stability, such as inserting canisters or sachets, which require additional insertion equipment and carry the risk of accidental ingestion. Complexity and costs also are reduced, since only one molded piece is needed for all scavenging needs.

Key benefits of CSP Technologies, Inc.’s new Activ-Seal closure include:

  • Metered dosing provides consumer convenience; orifice reducer opening can be tailored to various product sizes
  • No canister or sachet moving freely in the product bottle
  • Moisture and other gas scavenger materials cannot be removed
  • Hazard markings “Do Not Eat” are not required; adsorption material is secured to the underside of the orifice reducer and is invisible to the consumer
  • Technology fits within standard caps
  • No additional packaging insertion equipment needed
  • Integrated orifice reducer is becomes part of the product container
  • Can be applied with standard capping and induction sealing systems
  • Can release aroma for enhanced consumer experience

For over 30 years, CSP Technologies, Inc. has been a leader in delivering desiccant and other gas scavenging solutions to enhance product stability, extend shelf life and enable new packaging options for pharmaceutical manufacturers. The company’s Activ-Film™ materials, Activ-Blister™ solutions, and Activ-Polymer™ technologies are used by leading manufacturers to protect products against moisture, oxygen, VOC’s, and odors to ensure product stability and extend product shelf life.

See also

Aptar CSP Technologies’ Activ-Blister™ Solutions Now Available for Manufacturing in the EMEA Region

Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science solutions to ensure product protection, extend shelf life and improve patient experience, announces a new manufacturing site able to produce its Activ-Blister™ Solutions for oral slide dose drugs in Europe. The move is part of a key strategic effort to expand production of Activ-Blister™ technology globally.

Aptar CSP presents 'rethinking oral solid dose packaging' webinar

Aptar CSP Technologies – a leader in active packaging solutions that ensure product protection, enhance brand recognition and improve use experiences, and part of AptarGroup Inc – is presenting its Activ-Blister Solutions for the protection of moisture and oxygen-sensitive tablets and capsules, alongside FreeThink Technologies and its ASAPprime technology for accelerated shelf-life determination. The combination is a “right the first time” approach to stability challenges and blister package design that virtually eliminates protracted testing and costly reformulations.

CSP Technologies' focus for enhancing the shelf life for transdermal and oral solid dose drugs

Despite being two very different drug delivery platforms, oral solid doses and transdermal patches can face similar packaging headspace challenges that impact shelf life; besides moisture and oxygen ingress, exposure to certain conditions can lead to the formation of volatile organic compounds (VOCs) and other gases that, in turn, may interact with drug products and capsules, adversely impacting their stability.

  • Elias Bittan
  • Product Info
  • English
  • Created 30 Nov 2016
  • Modified 12 Dec 2016
  • Hits 2387